Physician profile
Wendy K Mccarty
NPI 1508195298
$3,307.10
in general payments reported to CMS, 2019-2025
29 companies · $811 in 2025
The $811 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $629 · 2022: $472 · 2023: $577 · 2024: $819 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $718.17 | 2021-2025 | |
| Pfizer INC. | $392.70 | 2021-2025 | |
| Novo Nordisk INC | $325.56 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $259.78 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $206.05 | 2021-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $196.71 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $173.11 | 2021-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.19 | 2021-2025 | Jardiance, Synjardy |
| Vanda Pharmaceuticals INC. | $106.85 | 2025 | Fanapt, Hetlioz |
| Medtronic, INC. | $77.80 | 2024-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $72.82 | 2021-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $66.37 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $58.81 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.10 | 2022 | |
| Axsome Therapeutics, INC. | $57.08 | 2022-2024 | Auvelity |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $54.90 | 2023-2024 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $54.26 | 2021 | |
| Merck Sharp & Dohme LLC | $44.13 | 2021 | |
| Astellas Pharma US INC | $39.65 | 2024-2025 | Veozah |
| Abiomed | $31.14 | 2024 | Impella |
| Dynavax Technologies Corporation | $30.00 | 2024 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $28.38 | 2021 | |
| Tolmar, INC. | $28.19 | 2024-2025 | Jatenzo |
| Janssen Pharmaceuticals, INC | $22.70 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.61 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $17.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.69 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.59 | 2025 | |
| Globus Medical, INC. | $15.34 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.